 | • レポートコード：QY2108PAL8793 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、120ページ • 納品方法：Eメール（納期：1日） • 産業分類：医薬品 |
| Single User | ￥585,000 (USD3,900) | ▷ お問い合わせ |
| Multi User | ￥877,500 (USD5,850) | ▷ お問い合わせ |
| Enterprise License | ￥1,170,000 (USD7,800) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| QYResearch社発行の当調査資料ではグローバルにおける癌治療用チェックポイント阻害剤の市場規模（2016年-2027年）と動向についてまとめました。中国市場については主要プレイヤーの市場シェア、癌治療用チェックポイント阻害剤の種類別市場規模（PD-1阻害剤、PD-L1阻害剤、CTLA-4阻害剤）、用途別市場規模（黒色腫治療、膀胱がん治療、その他）も掲載しています。他に、北米・アメリカ市場、ヨーロッパ市場、アジア太平洋・日本市場、中南米市場、中東・アフリカ市場の市場規模、グローバル市場機会・課題・リスク要因、バリューチェーン・販売チャネル、主要プレイヤーの情報なども掲載しています。 ・調査の概要 ・調査のサマリー ・世界の癌治療用チェックポイント阻害剤市場動向 ・グローバル主要プレイヤーの競争状況・市場シェア ・世界における癌治療用チェックポイント阻害剤の種類別市場規模（2016年-2027年）：PD-1阻害剤、PD-L1阻害剤、CTLA-4阻害剤 ・世界における癌治療用チェックポイント阻害剤の用途別市場規模（2016年-2027年）：黒色腫治療、膀胱がん治療、その他 ・癌治療用チェックポイント阻害剤の中国市場分析 - 癌治療用チェックポイント阻害剤の中国市場規模（2016年-2027年） - 中国における癌治療用チェックポイント阻害剤の主要プレイヤー別市場シェア - 中国における癌治療用チェックポイント阻害剤の種類別市場規模：PD-1阻害剤、PD-L1阻害剤、CTLA-4阻害剤 - 中国における癌治療用チェックポイント阻害剤の用途別市場規模：黒色腫治療、膀胱がん治療、その他 ・癌治療用チェックポイント阻害剤の北米市場（2016年-2027年） ・癌治療用チェックポイント阻害剤のヨーロッパ市場（2016年-2027年） ・癌治療用チェックポイント阻害剤のアジア太平洋市場（2016年-2027年） ・癌治療用チェックポイント阻害剤の中南米市場（2016年-2027年） ・癌治療用チェックポイント阻害剤の中東・アフリカ市場（2016年-2027年） ・主要プレイヤーの情報：Bristol-Myers Squibb(BMS)、Merck、Roche ・市場機会・課題・リスク要因分析 ・バリューチェーン・販売チャネル分析 ・... |
Checkpoint inhibitors for treating cancer is a type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells. These proteins help keep immune responses in check and can keep T cells from killing cancer cells. When these proteins are blocked, the “brakes” on the immune system are released and T cells are able to kill cancer cells better. Examples of checkpoint proteins found on T cells or cancer cells include PD-1/PD-L1 and CTLA-4/B7-1/B7-2.
The major players in global Checkpoint Inhibitors for Treating Cancer market include Bristol-Myers Squibb(BMS), Merck, etc., and the market concentration rate is high. North America is the main market, and occupies about 95% of the global market. PD-1 Inhibitors is the main type, with a share about 80%. Melanoma Treatment is the main application, which holds a share about 80%.
Market Analysis and Insights: Global and China Checkpoint Inhibitors for Treating Cancer Market
This report focuses on global and China Checkpoint Inhibitors for Treating Cancer market.
In 2020, the global Checkpoint Inhibitors for Treating Cancer market size was US$ 9690 million and it is expected to reach US$ 49050 million by the end of 2027, with a CAGR of 25.6% during 2021-2027. In China the Checkpoint Inhibitors for Treating Cancer market size is expected to grow from US$ XX million in 2020 to US$ XX million by 2027, at a CAGR of XX% during the forecast period.
Global Checkpoint Inhibitors for Treating Cancer Scope and Market Size
Checkpoint Inhibitors for Treating Cancer market is segmented by region (country), players, by Type, and by Application. Players, stakeholders, and other participants in the global Checkpoint Inhibitors for Treating Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type and by Application in terms of revenue and forecast for the period 2016-2027.
For China market, this report focuses on the Checkpoint Inhibitors for Treating Cancer market size by players, by Type, and by Application, for the period 2016-2027. The key players include the global and local players which play important roles in China.
Segment by Type
PD-1 Inhibitors
PD-L1 Inhibitors
CTLA-4 Inhibitors
Segment by Application
Melanoma Treatment
Bladder Cancer Treatment
Other
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
By Company
Bristol-Myers Squibb(BMS)
Merck
Roche
1 Study Coverage
1.1 Checkpoint Inhibitors for Treating Cancer Product Introduction
1.2 Market by Type
1.2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type
1.2.2 PD-1 Inhibitors
1.2.3 PD-L1 Inhibitors
1.2.4 CTLA-4 Inhibitors
1.3 Market by Application
1.3.1 Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Application
1.3.2 Melanoma Treatment
1.3.3 Bladder Cancer Treatment
1.3.4 Other
1.4 Study Objectives
1.5 Years Considered
2 Executive Summary
2.1 Global Checkpoint Inhibitors for Treating Cancer Market Size, Estimates and Forecasts
2.1.1 Global Checkpoint Inhibitors for Treating Cancer Revenue 2016-2027
2.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales 2016-2027
2.2 Global Checkpoint Inhibitors for Treating Cancer, Market Size by Region: 2016 VS 2021 VS 2027
2.3 Checkpoint Inhibitors for Treating Cancer Historical Market Size by Region (2016-2021)
2.3.1 Global Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario in Sales by Region: 2016-2021
2.3.2 Global Checkpoint Inhibitors for Treating Cancer Retrospective Market Scenario in Revenue by Region: 2016-2021
2.4 Checkpoint Inhibitors for Treating Cancer Market Estimates and Projections by Region (2022-2027)
2.4.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2022-2027)
2.4.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2022-2027)
3 Global Checkpoint Inhibitors for Treating Cancer Competitor Landscape by Players
3.1 Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Sales
3.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturer (2016-2021)
3.1.2 Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Manufacturer (2016-2021)
3.2 Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Revenue
3.2.1 Key Checkpoint Inhibitors for Treating Cancer Manufacturers Covered: Ranking by Revenue
3.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2016-2021)
3.2.3 Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers (2016-2021)
3.2.4 Global Checkpoint Inhibitors for Treating Cancer Market Concentration Ratio (CR5 and HHI) (2016-2021)
3.2.5 Global Top 10 and Top 5 Companies by Checkpoint Inhibitors for Treating Cancer Revenue in 2020
3.2.6 Global Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Global Checkpoint Inhibitors for Treating Cancer Price by Manufacturers
3.4 Global Checkpoint Inhibitors for Treating Cancer Manufacturing Base Distribution, Product Types
3.4.1 Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution, Headquarters
3.4.2 Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type
3.4.3 Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
3.5 Manufacturers Mergers & Acquisitions, Expansion Plans
4 Breakdown Data by Type (2016-2027)
4.1 Global Checkpoint Inhibitors for Treating Cancer Market Size by Type (2016-2021)
4.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2016-2021)
4.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2016-2021)
4.1.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type (2016-2021)
4.2 Global Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Type (2022-2027)
4.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2022-2027)
4.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2022-2027)
4.2.3 Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) Forecast by Type (2022-2027)
5 Breakdown Data by Application (2016-2027)
5.1 Global Checkpoint Inhibitors for Treating Cancer Market Size by Application (2016-2021)
5.1.1 Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2016-2021)
5.1.2 Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2016-2021)
5.1.3 Checkpoint Inhibitors for Treating Cancer Price by Application (2016-2021)
5.2 Checkpoint Inhibitors for Treating Cancer Market Size Forecast by Application (2022-2027)
5.2.1 Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2022-2027)
5.2.2 Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2022-2027)
5.2.3 Global Checkpoint Inhibitors for Treating Cancer Price Forecast by Application (2022-2027)
6 China by Players, Type and Application
6.1 China Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2016-2027
6.1.1 China Checkpoint Inhibitors for Treating Cancer Sales YoY Growth 2016-2027
6.1.2 China Checkpoint Inhibitors for Treating Cancer Revenue YoY Growth 2016-2027
6.1.3 China Checkpoint Inhibitors for Treating Cancer Market Share in Global Market 2016-2027
6.2 China Checkpoint Inhibitors for Treating Cancer Market Size by Players (International and Local Players)
6.2.1 China Top Checkpoint Inhibitors for Treating Cancer Players by Sales (2016-2021)
6.2.2 China Top Checkpoint Inhibitors for Treating Cancer Players by Revenue (2016-2021)
6.3 China Checkpoint Inhibitors for Treating Cancer Historic Market Review by Type (2016-2021)
6.3.1 China Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2016-2021)
6.3.2 China Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2016-2021)
6.3.3 China Checkpoint Inhibitors for Treating Cancer Price by Type (2016-2021)
6.4 China Checkpoint Inhibitors for Treating Cancer Market Estimates and Forecasts by Type (2022-2027)
6.4.1 China Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2022-2027)
6.4.2 China Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Type (2022-2027)
6.4.3 China Checkpoint Inhibitors for Treating Cancer Price Forecast by Type (2022-2027)
6.5 China Checkpoint Inhibitors for Treating Cancer Historic Market Review by Application (2016-2021)
6.5.1 China Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2016-2021)
6.5.2 China Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2016-2021)
6.5.3 China Checkpoint Inhibitors for Treating Cancer Price by Application (2016-2021)
6.6 China Checkpoint Inhibitors for Treating Cancer Market Estimates and Forecasts by Application (2022-2027)
6.6.1 China Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2022-2027)
6.6.2 China Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2022-2027)
6.6.3 China Checkpoint Inhibitors for Treating Cancer Price Forecast by Application (2022-2027)
7 North America
7.1 North America Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2016-2027
7.2 North America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
7.2.1 North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021)
7.2.2 North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021)
7.2.3 U.S.
7.2.4 Canada
8 Asia Pacific
8.1 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2016-2027
8.2 Asia Pacific Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Region
8.2.1 Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2016-2021)
8.2.2 Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2016-2021)
8.2.3 China
8.2.4 Japan
8.2.5 South Korea
8.2.6 India
8.2.7 Australia
8.2.8 Australia
8.2.9 Indonesia
8.2.10 Thailand
8.2.11 Malaysia
9 Europe
9.1 Europe Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2016-2027
9.2 Europe Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
9.2.1 Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021)
9.2.2 Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021)
9.2.3 Germany
9.2.4 France
9.2.5 U.K.
9.2.6 Italy
10 Latin America
10.1 Latin America Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2016-2027
10.2 Latin America Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
10.2.1 Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021)
10.2.2 Latin America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021)
10.2.3 Mexico
10.2.4 Brazil
10.2.5 Argentina
11 Middle East and Africa
11.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Size YoY Growth 2016-2027
11.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Market Facts & Figures by Country
11.2.1 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021)
11.2.2 Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021)
11.2.3 Turkey
11.2.4 Saudi Arabia
11.2.5 UAE
12 Company Profiles
12.1 Bristol-Myers Squibb(BMS)
12.1.1 Bristol-Myers Squibb(BMS) Corporation Information
12.1.2 Bristol-Myers Squibb(BMS) Description and Business Overview
12.1.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2016-2021)
12.1.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Products Offered
12.1.5 Bristol-Myers Squibb(BMS) Recent Development
12.2 Merck
12.2.1 Merck Corporation Information
12.2.2 Merck Description and Business Overview
12.2.3 Merck Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2016-2021)
12.2.4 Merck Checkpoint Inhibitors for Treating Cancer Products Offered
12.2.5 Merck Recent Development
12.3 Roche
12.3.1 Roche Corporation Information
12.3.2 Roche Description and Business Overview
12.3.3 Roche Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2016-2021)
12.3.4 Roche Checkpoint Inhibitors for Treating Cancer Products Offered
12.3.5 Roche Recent Development
12.11 Bristol-Myers Squibb(BMS)
12.11.1 Bristol-Myers Squibb(BMS) Corporation Information
12.11.2 Bristol-Myers Squibb(BMS) Description and Business Overview
12.11.3 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales, Revenue and Gross Margin (2016-2021)
12.11.4 Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Products Offered
12.11.5 Bristol-Myers Squibb(BMS) Recent Development
13 Market Opportunities, Challenges, Risks and Influences Factors Analysis
13.1 Checkpoint Inhibitors for Treating Cancer Industry Trends
13.2 Checkpoint Inhibitors for Treating Cancer Market Drivers
13.3 Checkpoint Inhibitors for Treating Cancer Market Challenges
13.4 Checkpoint Inhibitors for Treating Cancer Market Restraints
14 Value Chain and Sales Channels Analysis
14.1 Value Chain Analysis
14.2 Checkpoint Inhibitors for Treating Cancer Customers
14.3 Sales Channels Analysis
14.3.1 Sales Channels
14.3.2 Distributors
15 Research Findings and Conclusion
16 Appendix
16.1 Research Methodology
16.1.1 Methodology/Research Approach
16.1.2 Data Source
16.2 Author Details
16.3 Disclaimer
Table 1. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Type, 2016 VS 2021 VS 2027 (US$ Million)
Table 2. Major Manufacturers of PD-1 Inhibitors
Table 3. Major Manufacturers of PD-L1 Inhibitors
Table 4. Major Manufacturers of CTLA-4 Inhibitors
Table 5. Global Checkpoint Inhibitors for Treating Cancer Market Size Growth Rate by Application (2021-2027) & (g)
Table 6. Global Checkpoint Inhibitors for Treating Cancer Market Size by Region (g) & (US$ Million), 2016 VS 2021 VS 2027
Table 7. Global Checkpoint Inhibitors for Treating Cancer Sales by Regions (2016-2021) & (g)
Table 8. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Regions (2016-2021)
Table 9. Global Checkpoint Inhibitors for Treating Cancer Revenue by Regions (2016-2021) & (US$ Million)
Table 10. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Region (2022-2027) & (g)
Table 11. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Region (2022-2027)
Table 12. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Region (2022-2027) & (US$ Million)
Table 13. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Region (2022-2027)
Table 14. Global Checkpoint Inhibitors for Treating Cancer Sales by Manufacturers (2016-2021) (g)
Table 15. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturers (2016-2021)
Table 16. Ranking of Global Top Checkpoint Inhibitors for Treating Cancer Manufacturers by Revenue (US$ Million) in 2020
Table 17. Checkpoint Inhibitors for Treating Cancer Revenue by Manufacturers (2016-2021) (US$ Million)
Table 18. Checkpoint Inhibitors for Treating Cancer Revenue Share by Manufacturers (2016-2021)
Table 19. Global Checkpoint Inhibitors for Treating Cancer Manufacturers Market Concentration Ratio (CR5 and HHI) & (2016-2021)
Table 20. Global Checkpoint Inhibitors for Treating Cancer by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Checkpoint Inhibitors for Treating Cancer as of 2020)
Table 21. Key Manufacturers Checkpoint Inhibitors for Treating Cancer Price (2016-2021) (US$/mg)
Table 22. Checkpoint Inhibitors for Treating Cancer Manufacturers Manufacturing Base Distribution and Headquarters
Table 23. Manufacturers Checkpoint Inhibitors for Treating Cancer Product Type
Table 24. Date of International Manufacturers Enter into Checkpoint Inhibitors for Treating Cancer Market
Table 25. Manufacturers Mergers & Acquisitions, Expansion Plans
Table 26. Global Checkpoint Inhibitors for Treating Cancer Sales by Type (2016-2021) (g)
Table 27. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2016-2021)
Table 28. Global Checkpoint Inhibitors for Treating Cancer Revenue by Type (2016-2021) (US$ Million)
Table 29. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2016-2021)
Table 30. Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Type (2016-2021) & (US$/mg)
Table 31. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Type (2022-2027) & (g)
Table 32. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Type (2022-2027)
Table 33. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast V (2022-2027) & (US$ Million)
Table 34. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Type (2022-2027)
Table 35. Global Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) Forecast by Type (2022-2027) & (US$/mg)
Table 36. Global Checkpoint Inhibitors for Treating Cancer Sales by Application (2016-2021) (g)
Table 37. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2016-2021)
Table 38. Global Checkpoint Inhibitors for Treating Cancer Revenue by Application (2016-2021) (US$ Million)
Table 39. Global Checkpoint Inhibitors for Treating Cancer Revenue Share by Application (2016-2021)
Table 40. Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) by Application (2016-2021) & (US$/mg)
Table 41. Global Checkpoint Inhibitors for Treating Cancer Sales Forecast by Application (2022-2027) & (g)
Table 42. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share Forecast by Application (2022-2027)
Table 43. Global Checkpoint Inhibitors for Treating Cancer Revenue Forecast by Application (2022-2027) & (US$ Million)
Table 44. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share Forecast by Application (2022-2027)
Table 45. Global Checkpoint Inhibitors for Treating Cancer Average Selling Price (ASP) Forecast by Application (2022-2027) & (US$/mg)
Table 46. China Checkpoint Inhibitors for Treating Cancer Sales (g) of Key Companies (2016-2021)
Table 47. China Checkpoint Inhibitors for Treating Cancer Sales Share by Company (2016-2021)
Table 48. China Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) by Company (2016-2021)
Table 49. China Checkpoint Inhibitors for Treating Cancer Revenue Share by Company (2016-2021)
Table 50. China Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2016-2021)
Table 51. China Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2016-2021)
Table 52. China Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) Market Share by Type (2016-2021)
Table 53. China Checkpoint Inhibitors for Treating Cancer Price (US$/mg) by Type (2016-2021)
Table 54. China Checkpoint Inhibitors for Treating Cancer Sales (g) by Type (2022-2027)
Table 55. China Checkpoint Inhibitors for Treating Cancer Sales Share by Type (2022-2027)
Table 56. China Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) Market Share by Type (2022-2027)
Table 57. China Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2022-2027)
Table 58. China Checkpoint Inhibitors for Treating Cancer Price (US$/mg) by Type (2022-2027)
Table 59. China Checkpoint Inhibitors for Treating Cancer Sales (g) by Application (2016-2021)
Table 60. China Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2016-2021)
Table 61. China Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) Market Share by Application (2016-2021)
Table 62. China Checkpoint Inhibitors for Treating Cancer Price (US$/mg) by Application (2016-2021)
Table 63. China Checkpoint Inhibitors for Treating Cancer Sales (g) by Application (2022-2027)
Table 64. China Checkpoint Inhibitors for Treating Cancer Sales Share by Application (2022-2027)
Table 65. China Checkpoint Inhibitors for Treating Cancer Revenue (US$ Million) Market Share by Application (2022-2027)
Table 66. China Checkpoint Inhibitors for Treating Cancer Revenue Share by Application (2022-2027)
Table 67. China Checkpoint Inhibitors for Treating Cancer Price (US$/mg) by Application (2022-2027)
Table 68. North America Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021) & (g)
Table 69. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2016-2021)
Table 70. North America Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021) & (US$ Million)
Table 71. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2016-2021)
Table 72. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales by Region (2016-2021) & (g)
Table 73. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2016-2021)
Table 74. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue by Region (2016-2021) & (US$ Million)
Table 75. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2016-2021)
Table 76. Europe Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021) & (g)
Table 77. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2016-2021)
Table 78. Europe Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021) & (US$ Million)
Table 79. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2016-2021)
Table 80. Latin America Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021) & (g)
Table 81. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2016-2021)
Table 82. Latin Americaa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021) & (US$ Million)
Table 83. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2016-2021)
Table 84. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales by Country (2016-2021) & (g)
Table 85. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country (2016-2021)
Table 86. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue by Country (2016-2021) & (US$ Million)
Table 87. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country (2016-2021)
Table 88. Bristol-Myers Squibb(BMS) Corporation Information
Table 89. Bristol-Myers Squibb(BMS) Description and Business Overview
Table 90. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2016-2021)
Table 91. Bristol-Myers Squibb(BMS) Checkpoint Inhibitors for Treating Cancer Product
Table 92. Bristol-Myers Squibb(BMS) Recent Development
Table 93. Merck Corporation Information
Table 94. Merck Description and Business Overview
Table 95. Merck Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2016-2021)
Table 96. Merck Product
Table 97. Merck Recent Development
Table 98. Roche Corporation Information
Table 99. Roche Description and Business Overview
Table 100. Roche Checkpoint Inhibitors for Treating Cancer Sales (g), Revenue (US$ Million), Price (US$/mg) and Gross Margin (2016-2021)
Table 101. Roche Product
Table 102. Roche Recent Development
Table 103. Checkpoint Inhibitors for Treating Cancer Market Trends
Table 104. Checkpoint Inhibitors for Treating Cancer Market Drivers
Table 105. Checkpoint Inhibitors for Treating Cancer Market Challenges
Table 106. Checkpoint Inhibitors for Treating Cancer Market Restraints
Table 107. Checkpoint Inhibitors for Treating Cancer Customers List
Table 108. Checkpoint Inhibitors for Treating Cancer Distributors List
Table 109. Research Programs/Design for This Report
Table 110. Key Data Information from Secondary Sources
Table 111. Key Data Information from Primary Sources
List of Figures
Figure 1. Checkpoint Inhibitors for Treating Cancer Product Picture
Figure 2. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2020 & 2027
Figure 3. PD-1 Inhibitors Product Picture
Figure 4. PD-L1 Inhibitors Product Picture
Figure 5. CTLA-4 Inhibitors Product Picture
Figure 6. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2020 & 2027
Figure 7. Melanoma Treatment
Figure 8. Bladder Cancer Treatment
Figure 9. Other
Figure 10. Checkpoint Inhibitors for Treating Cancer Report Years Considered
Figure 11. Global Checkpoint Inhibitors for Treating Cancer Market Size, (US$ Million), 2016 VS 2021 VS 2027
Figure 12. Global Checkpoint Inhibitors for Treating Cancer Market Size 2016-2027 (US$ Million)
Figure 13. Global Checkpoint Inhibitors for Treating Cancer Sales 2016-2027 (g)
Figure 14. Global Checkpoint Inhibitors for Treating Cancer Market Size Market Share by Region: 2021 Versus 2027
Figure 15. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region (2016-2021)
Figure 16. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2020
Figure 17. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region (2016-2021)
Figure 18. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2020
Figure 19. Global Checkpoint Inhibitors for Treating Cancer Sales Share by Manufacturer in 2020
Figure 20. The Top 10 and 5 Players Market Share by Checkpoint Inhibitors for Treating Cancer Revenue in 2020
Figure 21. Checkpoint Inhibitors for Treating Cancer Market Share by Company Type (Tier 1, Tier 2 and Tier 3): 2016 VS 2020
Figure 22. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type (2016-2021)
Figure 23. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Type in 2020
Figure 24. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type (2016-2021)
Figure 25. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Type in 2020
Figure 26. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application (2016-2021)
Figure 27. Global Checkpoint Inhibitors for Treating Cancer Sales Market Share by Application in 2020
Figure 28. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application (2016-2021)
Figure 29. Global Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Application in 2020
Figure 30. China Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2016-2027 (g)
Figure 31. China Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2016-2027 (US$ Million)
Figure 32. China Checkpoint Inhibitors for Treating Cancer Market Share in Global Market 2016-2027
Figure 33. China 5 and 10 Largest Checkpoint Inhibitors for Treating Cancer Players Market Share by Revenue in Checkpoint Inhibitors for Treating Cancer in 2020
Figure 34. China Checkpoint Inhibitors for Treating Cancer Revenue Share by Type (2016-2021)
Figure 35. China Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate by Type in 2016 & 2020
Figure 36. China Checkpoint Inhibitors for Treating Cancer Revenue Share by Application (2016-2021)
Figure 37. China Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate by Application in 2016 & 2020
Figure 38. North America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2016-2021 (g)
Figure 39. North America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2016-2021 (US$ Million)
Figure 40. North America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2020
Figure 41. North America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2020
Figure 42. U.S. Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 43. U.S. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 44. Canada Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 45. Canada Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 46. Europe Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2016-2021 (g)
Figure 47. Europe Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2016-2021 (US$ Million)
Figure 48. Europe Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2020
Figure 49. Europe Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2020
Figure 50. Germany Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 51. Germany Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 52. France Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 53. France Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 54. U.K. Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 55. U.K. Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 56. Italy Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 57. Italy Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 58. Russia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 59. Russia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 60. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2016-2021 (g)
Figure 61. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2016-2021 (US$ Million)
Figure 62. Asia Pacific Checkpoint Inhibitors for Treating Cancer Sales Market Share by Region in 2020
Figure 63. Asia Pacific Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Region in 2020
Figure 64. China Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 65. China Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 66. Japan Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 67. Japan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 68. South Korea Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 69. South Korea Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 70. India Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 71. India Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 72. Australia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 73. Australia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 74. China Taiwan Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 75. China Taiwan Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 76. Indonesia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 77. Indonesia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 78. Thailand Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 79. Thailand Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 80. Malaysia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 81. Malaysia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 82. Latin America Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2016-2021 (g)
Figure 83. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2016-2021 (US$ Million)
Figure 84. Latin America Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2020
Figure 85. Latin America Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2020
Figure 86. Mexico Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 87. Mexico Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 88. Brazil Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 89. Brazil Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 90. Argentina Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 91. Argentina Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 92. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Growth Rate 2016-2021 (g)
Figure 93. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate 2016-2021 (US$ Million)
Figure 94. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Sales Market Share by Country in 2020
Figure 95. Middle East and Africa Checkpoint Inhibitors for Treating Cancer Revenue Market Share by Country in 2020
Figure 96. Turkey Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 97. Turkey Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 98. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 99. Saudi Arabia Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 100. UAE Checkpoint Inhibitors for Treating Cancer Sales Growth Rate (2016-2021) (g)
Figure 101. UAE Checkpoint Inhibitors for Treating Cancer Revenue Growth Rate (2016-2021) (US$ Million)
Figure 102. Checkpoint Inhibitors for Treating Cancer Value Chain
Figure 103. Channels of Distribution
Figure 104. Distributors Profiles
Figure 105. Bottom-up and Top-down Approaches for This Report
Figure 106. Data Triangulation
Figure 107. Key Executives Interviewed
がんチューブリン阻害剤の世界市場 2020年 Market Overview The global Cancer Tubulin Inhibitors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Cancer Tubulin Inhi…- がんmTOR阻害剤の世界市場 2020年 Market Overview The global Cancer mTOR Inhibitors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Cancer mTOR Inhibitors…
- レニン阻害剤の世界市場 2020年 Market Overview The Renin-Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…
- PD-L1阻害剤の世界市場 2020年 Market Overview The PD-L1 Inhibitors market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trad…
- チロシンキナーゼ阻害剤の世界市場 2020年 Market Overview The global Tyrosine Kinase Inhibitors market size is expected to gain market growth in the forecast period of 2020 to 2025, with a CAGR of xx% in the forecast period of 2020 to 2025 and will expected to reach USD xx million by 2025, from USD xx million in 2019. The Tyrosine Kinase In…